Can DNA-Guided dosing save lives? new study targets african americans
NCT ID NCT03225820
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether giving doctors genetic information about their African American patients can help them prescribe the blood thinner warfarin more safely and effectively. Researchers will track how often doctors use this genetic guidance and whether it leads to better health outcomes. The study involves 1,000 African American adults at multiple hospitals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2017
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients will comprise the eligible patient population of this study. These patients will be identified through recruitment from the inpatient medicine services at each of the respective institutions, or from relevant clinics or clinical populations that are likely to initiate, or are newly-starting, warfarin therapy.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients must be at least 18 years of age. * Patients must self-identify as African American Exclusion Criteria: * Patients who have undergone, or are being actively considered for, liver or kidney transplantation. * Patients with known active or prior leukemia. * Inability to understand and give informed consent to participate. * For patients being recruited to the warfarin sub-study, those with a glomerular filtration rate or creatinine clearance \<30 mL/min34.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Information seeking behavior are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Northwestern University
NOT_YET_RECRUITINGChicago, Illinois, 60611, United States
-
The University of Illinois at Chicago
RECRUITINGChicago, Illinois, 60607, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.